145.00
3.16 (2.23%)
| Previous Close | 141.84 |
| Open | 142.97 |
| Volume | 1,983,725 |
| Avg. Volume (3M) | 1,015,263 |
| Market Cap | 14,457,325,568 |
| Price / Earnings (TTM) | 34.61 |
| Price / Earnings (Forward) | 19.84 |
| Price / Sales | 5.40 |
| Price / Book | 4.71 |
| 52 Weeks Range | |
| Earnings Date | 5 Feb 2026 |
| Profit Margin | 12.68% |
| Operating Margin (TTM) | 4.14% |
| Diluted EPS (TTM) | 2.95 |
| Quarterly Revenue Growth (YOY) | 11.10% |
| Quarterly Earnings Growth (YOY) | -81.80% |
| Total Debt/Equity (MRQ) | 19.45% |
| Current Ratio (MRQ) | 3.13 |
| Operating Cash Flow (TTM) | 529.90 M |
| Levered Free Cash Flow (TTM) | 235.48 M |
| Return on Assets (TTM) | 8.75% |
| Return on Equity (TTM) | 12.43% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Bullish | |
| Stock | Neurocrine Biosciences, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 2.00 |
|
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Mid Core |
| % Held by Insiders | 1.06% |
| % Held by Institutions | 98.86% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Los Angeles Capital Management Llc | 30 Sep 2025 | 1,202,756 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 203.00 (Citigroup, 40.00%) | Buy |
| Median | 180.00 (24.14%) | |
| Low | 164.00 (Canaccord Genuity, 13.10%) | Buy |
| Average | 184.00 (26.90%) | |
| Total | 11 Buy, 2 Hold | |
| Avg. Price @ Call | 143.56 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 08 Jan 2026 | 175.00 (20.69%) | Hold | 135.99 |
| 11 Nov 2025 | 173.00 (19.31%) | Buy | 147.29 | |
| HC Wainwright & Co. | 17 Dec 2025 | 198.00 (36.55%) | Buy | 141.70 |
| Mizuho | 12 Dec 2025 | 175.00 (20.69%) | Hold | 152.80 |
| Stifel | 11 Dec 2025 | 188.00 (29.66%) | Buy | 154.75 |
| 29 Oct 2025 | 183.00 (26.21%) | Buy | 138.02 | |
| RBC Capital | 08 Dec 2025 | 180.00 (24.14%) | Buy | 154.99 |
| 29 Oct 2025 | 160.00 (10.34%) | Buy | 138.02 | |
| TD Cowen | 05 Dec 2025 | 200.00 (37.93%) | Buy | 155.51 |
| JP Morgan | 03 Nov 2025 | 179.00 (23.45%) | Buy | 141.96 |
| Truist Securities | 30 Oct 2025 | 172.00 (18.62%) | Buy | 138.04 |
| Canaccord Genuity | 29 Oct 2025 | 164.00 (13.10%) | Buy | 138.02 |
| Citigroup | 29 Oct 2025 | 203.00 (40.00%) | Buy | 138.02 |
| 21 Oct 2025 | 175.00 (20.69%) | Buy | 142.65 | |
| Needham | 29 Oct 2025 | 184.00 (26.90%) | Buy | 138.02 |
| Piper Sandler | 29 Oct 2025 | 179.00 (23.45%) | Buy | 138.02 |
| UBS | 09 Oct 2025 | 195.00 (34.48%) | Buy | 138.47 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |